MURA | Mural Oncology plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.26 - 3.42
52 Week Range	2.8800 - 6.25
Beta	0.89
Implied Volatility	244.34%
IV Rank	18.56%
Day's Volume	98,553
Average Volume	86,404
Shares Outstanding	17,037,992
Market Cap	57,418,033
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-11-16

Valuation
Profitability
Growth
Health
P/E Ratio	-0.37
Forward P/E Ratio	N/A
EPS	-9.02
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	107
Country	Ireland
Website	MURA

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

*Chart delayed

Analyzing fundamentals for MURA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see MURA Fundamentals page.

Watching at MURA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on MURA Technicals page.